Comment


2025-02-21

Comment on Björn Borg’s Year-End Report for 2024
Read more

Comment


2025-02-21

Kommentar på Luxbrights bokslutskommuniké för år 2024
Read more

Analysis


2025-02-21

Umida Group Q4-24
Read more

Comment


2025-02-21

Analyst Group inleder analysbevakning på Cedergrenska och kommenterar Cedergrenskas Q2-rapport för år 2024/25
Read more

Comment


2025-02-20

Kommentar på First Ventures Q4-rapport
Read more

Comment


2025-02-20

Kommentar på Zoomabilitys Q4-rapport
Read more

Comment


2025-02-20

Kommentar på Titanias Q4-rapport
Read more

Analysis


2025-02-20

Nosa Plugs Q4-24
Read more

Text interview


2025-02-19

Intervju med Desert Controls VD Ole Kristian Sivertsen
Read more

Comment


2025-02-18

Kommentar på CirChems Q4-rapport
Read more

Comment


2025-02-17

Kommentar på Obducats Q4-rapport och företrädesemisson
Read more

Analysis


2025-02-17

Elektroimportøren
Read more

Comment


2025-02-14

Comment on Nosa Plugs Q4 Report
Read more

Comment


2025-02-14

Kommentar på Nosa Plugs Q4-rapport
Read more

Comment


2025-02-14

Kommentar på Umidas Q4-rapport 2024
Read more

Comment


2025-02-13

Comment on Eevia Health’s Initiated Divestment of Assets Related to Berry-Extract Manufacturing
Read more

Comment


2025-02-12

Comment on Eevia Health’s Term Sheet Agreement with an International Partner and the Announced Insider Transactions
Read more

Analysis


2025-02-12

SeaBird Exploration
Read more

Analysis


2025-02-12

Vow
Read more

Analysis


2025-02-12

The Kingfish Company
Read more

Comment


2025-02-11

Comment on Eevia Health’s New Sales Orders Totaling SEK 619k (EUR 54k) and Participation in leading trade fair BIOFACH
Read more

Comment


2025-02-11

Analyst Group inleder analysbevakning på Hifab och kommenterar Hifabs Q4-rapport
Read more

Analysis


2025-02-11

Cyviz
Read more

Text interview


2025-02-10

Intervju med Envipcos Corporate Strategy & Investor Relations Director Mikael Clement
Read more

Text interview


2025-02-07

Intervju med PolarCools VD Erik Andersson
Read more

Analysis


2025-02-07

Medclair
Read more

Comment


2025-02-06

Comment on Eevia Health’s Q4-report
Read more

Text interview


2025-02-05

Intervju med Goodbye Kansas Groups VD Stefan Danieli
Read more

Comment


2025-02-05

Comment on Eevia Health’s Divestment of the Eye-Health Candidate Retinari™
Read more

Analysis


2025-02-04

Navamedic
Read more

Comment


2025-02-04

Analyst Group kommenterar utfallet i AcuCorts företrädesemission samt positiva resultat från Fas IV-studie
Read more

Video


2025-01-31

Intervju med Neovicis VD Jan Berggren
Read more

Video


2025-01-30

Interview with Eevia Health’s CEO Stein Ulve
Read more

Comment


2025-01-29

Kommentar på Nosa Plugs lansering av NOSA Nozoil
Read more

Comment


2025-01-29

Comment on Eevia Health’s New Orders of SEK 763k (EUR 66k) and Newly Acquired Customer
Read more

Rights Issue


2025-01-28

Rights Issue: Eevia Health
Read more

Analysis


2025-01-28

Eevia Health
Read more

Comment


2025-01-27

Kommentar på Ramlösa Shippings investering i Capito Capital A/S
Read more

Text interview


2025-01-27

Interview with BactiQuant’s CEO Morten Miller
Read more

Analysis


2025-01-27

Neovici
Read more

Text interview


2025-01-23

Intervju med Elicera Therapeutics VD Jamal El-Mosleh
Read more

Comment


2025-01-22

Comment on the outcome of STENOCARE’s Conditional Rights Issue
Read more

Text interview


2025-01-22

Interview with Trifork’s Group Investment Director Frederik Svanholm
Read more

Text interview


2025-01-20

Intervju med Implanticas VD Peter Forsell
Read more

Text interview


2025-01-17

Intervju med Gigasuns VD Max Metelius
Read more

Analysis


2025-01-17

Nosa Plugs
Read more

Comment


2025-01-10

Kommentar på Luxbrights typgodkännande för en ny rörmodell och nya ordrar om 1 MSEK från Fisica Inc.
Read more

Rights Issue


2025-01-09

Emission: Stenocare
Read more

Comment


2025-01-03

Kommentar på Kinda Braves säkerställda finansiering fram till lanseringen av ”Hela” samt det ökade globala intresset för flaggskeppstiteln
Read more

Comment


2024-12-27

Kommentar på Tangiamos omvända förvärv av Co-Properties
Read more

Comment


2024-12-23

Kommentar på Neovicis avtal om förvärv av Wraptech och upptaget lån om 11 MSEK
Read more

Comment


2024-12-20

Comment on STENOCARE’s Announcement of a Conditional Rights Issue of up to DKK 20.2m
Read more

Comment


2024-12-19

Kommentar på AcuCorts inlämnade iPSP-ansökan till FDA
Read more

Comment


2024-12-18

Kommentar på Obducats senaste ordrar
Read more

Comment


2024-12-17

Kommentar på Titanias förvärv av Byggmästaren 2 i Solna
Read more

Comment


2024-12-17

Comment on STENOCARE’s Approval for a new Medical Cannabis CBD100 oil
Read more

Comment


2024-12-13

Comment on Pharma Equity Group’s New Execution Strategy
Read more

Analysis


2024-12-11

Tangiamo Touch Q3-24
Read more

Text interview


2024-12-11

Interview with MPC Container Ships’ Co-CEO and CFO Moritz Fuhrmann
Read more

Text interview


2024-12-10

Interview with Icelandic Salmon’s CEO Björn Hembre
Read more

Comment


2024-12-09

Kommentar på Tangiamos utvecklingsavtal med Tech (Macau) Ltd
Read more

Analysis


2024-12-06

Zoomability Q3-24
Read more

Analysis


2024-12-06

Analysartikel – Phase Holographic Imaging
Read more

Rights Issue


2024-12-06

Emission: Phase Holographic Imaging
Read more

Rights Issue


2024-12-06

IPO: SEHED Byggmästargruppen
Read more

Analysis


2024-12-05

CirChem Q3-24
Read more

Analysis


2024-12-05

AcuCort Q3-24
Read more

Comment


2024-12-04

Comment on ODI Pharma’s Update on Poland’s Expanding Medical Cannabis Market
Read more

Text interview


2024-12-04

Interview with Glaston’s CEO Toni Laaksonen
Read more

Analysis


2024-12-04

MoveByBike
Read more

Text interview


2024-12-03

Interview with Aspo’s CEO Rolf Jansson
Read more

Comment


2024-12-02

Kommentar på AcuCorts Q3-rapport samt företrädesemission
Read more

Analysis


2024-12-02

ODI Pharma Q1-24/25
Read more

Comment


2024-12-02

Comment on that STENOCARE’s Astrum Oil has been Approved for Sales in Norway
Read more

Analysis


2024-12-02

Ramlösa Shipping Q3-24
Read more

Analysis


2024-12-02

Kinda Brave Q3-24
Read more

Comment


2024-11-29

Comment on the Outcome of Irisity’s Rights Issue
Read more

Comment


2024-11-29

Kommentar på Tangiamos Q3-rapport
Read more

Comment


2024-11-28

Kommentar på Zoomabilitys Q3-rapport
Read more

Analysis


2024-11-28

Embark Group Q3-24
Read more